Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Shares Outstanding (Weighted Average) (2021 - 2026)

Zentalis Pharmaceuticals has reported Shares Outstanding (Weighted Average) over the past 6 years, most recently at $70.3 million for Q1 2026.

  • For Q1 2026, Shares Outstanding (Weighted Average) fell 1.97% year-over-year to $70.3 million; the TTM value through Mar 2026 reached $70.3 million, down 1.97%, while the annual FY2025 figure was $71.9 million, 1.11% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q1 2026 was $70.3 million at Zentalis Pharmaceuticals, down from $71.9 million in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $72.1 million in Q3 2025 and troughed at $45.2 million in Q1 2022.
  • A 5-year average of $64.2 million and a median of $70.3 million in 2026 define the central range for Shares Outstanding (Weighted Average).
  • Biggest five-year swings in Shares Outstanding (Weighted Average): soared 31.02% in 2023 and later decreased 1.97% in 2026.
  • Year by year, Shares Outstanding (Weighted Average) stood at $52.9 million in 2022, then rose by 23.75% to $65.4 million in 2023, then grew by 8.67% to $71.1 million in 2024, then increased by 1.11% to $71.9 million in 2025, then decreased by 2.23% to $70.3 million in 2026.
  • Business Quant data shows Shares Outstanding (Weighted Average) for ZNTL at $70.3 million in Q1 2026, $71.9 million in Q4 2025, and $72.1 million in Q3 2025.